Glucarpidase Inhibitors
1 drugsAbout Glucarpidase
Glucarpidase is a recombinant enzyme that rapidly hydrolyzes methotrexate, a folate analog used in chemotherapy and autoimmune disease treatment. It addresses methotrexate toxicity caused by impaired kidney function or high doses, preventing serious side effects by reducing methotrexate levels.
Glucarpidase is a drug target of clinical importance in optimizing the safety of methotrexate-based therapies. Currently, there is no genetic evidence available linking Glucarpidase to specific diseases, highlighting a need for further investigation.
Glucarpidase is exclusively targeted by VORAXAZE, an FDA-approved biologic drug. BTG INTERNATIONAL INC is the sole company in this therapeutic area, which is classified as 'Other'.
Top Glucarpidase Drugs
BTG INTERNATIONAL INC is the only company with an approved drug targeting Glucarpidase.
The single-player market suggests high barriers to entry or limited commercial attractiveness.
Glucarpidase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Glucarpidase, using enzyme modality.
The lack of modality diversity indicates a potential opportunity for small molecule or alternative biologic approaches.
Glucarpidase Clinical Trials 7 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Glucarpidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 3 | 0 | 2 | 0 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Glucarpidase Drug Approval Timeline (2012 - 2012)
VORAXAZE was first approved in 2012 and remains the most recent approval.
The lack of recent approvals suggests market saturation or limited innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Glucarpidase. A trial counts if an approved drug acting on Glucarpidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.